Immunology
Variant-resistant COVID-19 vaccines could be effective, cheap to make
Researchers have collaborated to create a new COVID-19 vaccine platform containing antigens against the fusion protein of the SARS-CoV-2 virus that could be effective against variants of the virus. The research was published online on April 15 in the Proceedings of the National Academy of Sciences. Read More
Will preprints have a lasting effect on publishing beyond COVID-19?
During the COVID-19 pandemic, 25% of all COVID-19-related scientific manuscripts were shared on preprint servers, a steep increase from previous usage and relative to traditional peer-review journals. An international team of researchers explored the critical role of preprint servers in disseminating epidemic-related information in an article published in PLOS Biology on April 2. Read More
New method creates insights into T-cell responses to infections
Researchers have developed a method to study the specialization of T cells in the context of acute versus chronic infections. They found that T-cell responses can vary based on receptor signal strength and the persistence of infection in a study published in eLife on March 8. Read More
FDA committee gives nod to Janssen COVID-19 vaccine
A single-shot COVID-19 vaccine from Johnson & Johnson's Janssen Biotech subsidiary has received a positive recommendation from a U.S. Food and Drug Administration (FDA) advisory committee. Should the FDA grant the product emergency use authorization, the vaccine candidate will become the third to be made available in the U.S. Read More
New open-access toolkit helps research labs study SARS-CoV-2
One of the most important factors in fighting the COVID-19 pandemic is large-scale scientific collaborations and knowledge sharing. One international group of researchers has made its simple, robust toolkit available to laboratories around the globe that are unaccustomed to working with coronaviruses. The details can be found in a PLOS Biology paper published on February 25. Read More
Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy. Read More
Proteomics helps researchers pick the best anti-SARS-CoV-2 nanobodies
A new high-throughput proteomics-based strategy to identify tiny antibody fragments -- called nanobodies -- may provide an efficient and effective method for developing therapeutics against the deadly SARS-CoV-2 virus -- including variants. The findings were published in Cell Systems on February 15. Read More
Scientists identify missing molecular links to SARS-CoV-2, host interactions
Researchers have identified interactions between short viral proteins and receptors that facilitate the entry of the SARS-CoV-2 virus into a host. This evidence of molecular links, published in Science Signaling on February 12, may help scientists identify drugs that are highly effective at blocking the virus. Read More
NIH adds long-acting antibody COVID-19 therapy to ACTIV-3 master protocol
The National Institutes of Health (NIH) has begun a new arm of its master protocol, the Accelerating COVID-19 Therapeutic Interventions and Vaccines 3 (ACTIV-3) study, which evaluates the safety and efficacy of an investigational long-acting antibody combination for the treatment of patients hospitalized with COVID-19. Read More
Deep-learning approach points the way to faster COVID-19 vaccines
A novel deep neural network can target the most promising multiepitope COVID-19 vaccine candidates in a matter of seconds. The new artificial intelligence framework, which was described in Scientific Reports on February 5, may give scientists an edge in the race against SARS-CoV-2 and its variants by reducing the time from vaccine design to clinical trials. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter